US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

42.61

+0.93212.24%

Post-market: 42.680.0729+0.17%16:10 EDT

Volume:561

Turnover:23.88K

Market Cap:118.32M

PE:- -

High:42.68

Open:42.52

Low:42.52

Close:41.68

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.36

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

EBR Systems advances FDA approval process for new WiSE manufacturing site

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

Guardant Health (GH) Receives a Buy from Bernstein

LivaNova (LIVN) Looks Mispriced Following A Pullback In A Stronger Long Term Story

Simply Wall St.

FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches

LivaNova to Discuss Third-Quarter 2026 Results on Conference Call

LivaNova to Announce Third-Quarter 2026 Results

THOMSON REUTERS

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live

Travere Therapeutics receives notice of allowance for FILSPARI patent

Travere Therapeutics - Receives USPTO Notice of Allowance for Filspari Patent in FSGS

Travere Therapeutics, - Receives Uspto Notice of Allowance for Filspari Patent in Fsgs

THOMSON REUTERS

Travere Gets USPTO Notice of Allowance for Filspari Use in FSGS Patent Application

Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II

New precision medicine venture gives Syngenis added firepower

The West Australian

Novo Nordisk CEO Signals Deal-Making Ambitions to Strengthen Drug Pipeline

Travere Therapeutics Announces Planned Chief Executive Officer Transition

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/LFSC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":42.6071,"timestamp":1791576000000,"preClose":41.675,"halted":0,"volume":561,"hourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"delay":0,"changeRate":0.022365926814637206,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":0.9321,"latestTime":"10-09 16:00:00 EDT","open":42.515,"high":42.68,"low":42.515,"amount":23883,"amplitude":0.003959,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":41.675,"sharesOutstanding":2657035,"nav":41.68,"aum":115746818.8,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.68,"preClose":42.6071,"latestTime":"16:10 EDT","volume":1,"amount":42.6071,"timestamp":1791576604081,"change":0.0729,"changeRate":0.001711,"amplitude":0},"volumeRatio":0.358558},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.358558,"shares":2777035,"dividePrice":0,"high":42.68,"amplitude":0.003959,"preClose":41.675,"low":42.515,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":42.6071,"eps":0,"divideRate":0,"volume":561,"delay":0,"ttmEps":0,"open":42.515,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":43.401,"twentyDayClose":45.3275,"sixtyDayClose":44.9054},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","FRTY","BK4585","BK4559","MRNX","IDNA","XLVX","IBB","MEDI","BK4557","BBP","LU1983299246.USD","BK4007","RSPH","LABU","IYH","LU2324357040.USD","TBXU","LFSC","PSCH","BMED","TECB","TEVA","IEIH","GNMX","BK4588","BK4584","GDOC","SYNB","MRNY","PINK","NVIB","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNMX","BK4588","TECB","LABU","MRNX","XLVX","TBXU","PSCH","BK4007","PINK","GDOC","IEIH","BK4585","IYH","BMED","RSPH","LFSC","TBPH","BBP","MEDI","IBB","NVIB","SYNB","MRNY","FRTY","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","LABU","FRTY","LFSC","IYH","PSCH","BBP","SYNB","IBB","XLVX","BK4588","TBXU","PINK","MEDI","BK4585","TECB","BMED","NVIB","GNMX","MRNX","RSPH","IEIH","GDOC","EES","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670740486","title":"Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670740486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670740486?lang=en_us&edition=fundamental","pubTime":"2026-09-28 05:30","pubTimestamp":1790544629,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE). Oncolyti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncolytics-biotech-oncy-and-spyre-therapeutics-syre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","SYRE","LU0029874061.USD","BK4588","LABU","BK4139","ONCY","XBI","XLV","BK4585","BK4581","HCSG","BK4137","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670745514","title":"Guardant Health (GH) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670745514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670745514?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:15","pubTimestamp":1790432125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Guardant Health, with a price target of $210.00. The company...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","FFOX","BK4588","BK4551","BK4196","EKG","GNOM","LU0889565916.HKD","LU0109394709.USD","GH","BK4585","GNMX","BK4535","HELX","LU0320765992.SGD","GDOC","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670415345","title":"LivaNova (LIVN) Looks Mispriced Following A Pullback In A Stronger Long Term Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2670415345","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670415345?lang=en_us&edition=fundamental","pubTime":"2026-09-25 01:34","pubTimestamp":1790271287,"startTime":"0","endTime":"0","summary":"LivaNova (LIVN) is back on investor radar after recent share moves, with the price near $77.16 and year-to-date total return around 27%, inviting closer attention to fundamentals.\nLivaNova’s recent share price softness, with the 1 month share price return down 1.41% and 3 month share price return down 4.80%, comes against a stronger backdrop. This is highlighted by a 27.24% year to date share price gain and 44.96% 1 year total shareholder return, which signals momentum has built over the past...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice2-card/1788934354473","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6021000-choice2-card/1788934354473"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/livanova-livn-looks-mispriced-following-a-pullback-in-a-stro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-livn/livanova/news/livanova-livn-looks-mispriced-following-a-pullback-in-a-stro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065171402.SGD","BK4082","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LFSC","LIVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669499070","title":"FDA Advisors Said it Should Approve the Grail Multicancer Blood Test. the Stock Rises Sharply.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669499070","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669499070?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:52","pubTimestamp":1790261520,"startTime":"0","endTime":"0","summary":"Mizuho's Bradley Bowers thinks the boost will be substantial. He wrote Tuesday that sales doubled in the launch years of other cancer-screening products-like colon cancer stool test Cologuard from the Exact Sciences unit of Abbott, or the colon cancer blood test Shield from Guardant Health.Galleri screens a person's blood sample for bits of DNA showing features typical of cancer cells. It tells you if it has found a general signal of cancer somewhere in your body-\"Cancer Signal Detected\"-and makes its best guess at the kind of tissue where the cancer is hiding.Clinical trials showed Galleri can detect cancers for which there is no standard screen, such as cancer of the ovary or pancreas. Grail's two big clinical trials showed that it rarely tells you that you have cancer when you don't. When you do have cancer, the test finds it on average about 50% of the 60% of the time.That is good performance, compared with other widely used screens, like the mammogram. Grail plans to tell customer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B4R5TH58.HKD","LABU","BK4568","LU0889565916.HKD","GNMX","SGXZ41872573.SGD","IE00B2B36J28.USD","LU2237957811.SGD","LU2468319806.SGD","LU2089984988.USD","BK4082","EKG","TMED","LU1989763690.USD","ABT","BK4139","BK4588","GH","IE0002141913.USD","IHI","LU0320765489.SGD","BK4535","SG9999002224.SGD","LU2112291526.USD","LFSC","BK4551","LU1670627923.USD","LU0211331839.USD","BK4196","BK4581","GNOM","LU0289739699.SGD","SG9999002232.USD","PJP","LU0882574055.USD","LU2324357040.USD","SGXZ23171101.USD","LU1691799644.USD","BK4585","GRAL","FFOX","PTH","LU0868494617.USD","LU1721429402.USD","LU1721429741.USD","SG9999004303.SGD","HELX","LU1061106388.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669770466","title":"Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669770466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669770466?lang=en_us&edition=fundamental","pubTime":"2026-09-24 17:30","pubTimestamp":1790242220,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Royalty Pharma (RPRX), Travere Therapeutics (TVTX) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-travere-therapeutics-tvtx-and-veeva-systems-veev-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FFTY","LABU","RPRX","LU0170899867.USD","BK4007","HCSG","PBE","BK4137","LU0058720904.USD","VEEV","EKG","BK4167","BK4504","BK4534","BK4139","BK4588","LFSC","LU0266013472.USD","LU0289739699.SGD","BK4581","XBI","LU1989764748.USD","BK4528","XLV","LU1989764664.SGD","LU0006306889.USD","BK4613","LU0106261372.USD","BK4585","TVTX","LGHT","IHE","LU0029874061.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669437128","title":"Mesoblast Wins FDA Nod for New Potency Assay on Ryoncil Batches","url":"https://stock-news.laohu8.com/highlight/detail?id=2669437128","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669437128?lang=en_us&edition=fundamental","pubTime":"2026-09-24 08:30","pubTimestamp":1790209807,"startTime":"0","endTime":"0","summary":"An announcement from Mesoblast Limited ( ($AU:MSB) ) is now available. Mesoblast has secured U.S. FDA approval for a new T-cell Proliferation Inhib...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mesoblast-wins-fda-nod-for-new-potency-assay-on-ryoncil-batches?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LABU","NVIB","IDNA","BK4139","LFSC","MEDI","MRNY","GNMX","RSPH","IEIH","MESO","FRTY","MRNX","GDOC","TBXU","XLVX","BBP","BK4588","PSCH","PINK","SYNB","IYH","BK4585","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669864994","title":"LivaNova to Discuss Third-Quarter 2026 Results on Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2669864994","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669864994?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:02","pubTimestamp":1790168546,"startTime":"0","endTime":"0","summary":"LivaNova to discuss third-quarter 2026 results on conference callLivaNova will release third-quarter 2026 results ahead of a conference call on Nov. 4, 2026.Results call scheduled for 1 p.m. GMT on No","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL8QDqLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU2065171402.SGD","LIVN","LU2065170008.USD","BK4082","LFSC","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486182","title":"LivaNova to Announce Third-Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486182","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486182?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA55JRCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LFSC","LIVN","LU2065171311.SGD","LU2065170008.USD","BK4082","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669848334","title":"Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI","url":"https://stock-news.laohu8.com/highlight/detail?id=2669848334","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669848334?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:49","pubTimestamp":1790164165,"startTime":"0","endTime":"0","summary":"Travere Therapeutics  said Wednesday that it received a notice of allowance from the US Patent and Trademark Office for certain methods of using FILSPARI in focal segmental glomerulosclerosis, a rare kidney disease.The company said it expects to receive the patent, which is expected to provide US patent coverage for certain methods of using FILSPARI in the disease into October 2037, after paying the issue fee and completing standard USPTO post-allowance processing.Travere said it expects to submit the patent for listing in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations after receiving the grant.Shares of the company were down 1.3% in Wednesday's premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FFTY","LENZ","TVTX","BK4007","USRD","BK4139","BK4539","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669448832","title":"Travere Therapeutics receives notice of allowance for FILSPARI patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2669448832","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669448832?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:10","pubTimestamp":1790161811,"startTime":"0","endTime":"0","summary":"Travere Therapeutics (TVTX) announced that the United States Patent and Trademark Office issued a Notice of Allowance for U.S. Patent Application N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-receives-notice-of-allowance-for-filspari-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-receives-notice-of-allowance-for-filspari-patent-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVTX","LENZ","BK4539","BK4007","BK4139","LFSC","USRD","FFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669002651","title":"Travere Therapeutics - Receives USPTO Notice of Allowance for Filspari Patent in FSGS","url":"https://stock-news.laohu8.com/highlight/detail?id=2669002651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669002651?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161518,"startTime":"0","endTime":"0","summary":"BRIEF-Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGSSept 23 (Reuters)-Travere Therapeutics, Inc.TVTX.O:TRAVERE THERAPEUTICS, - RECEIVES USPTO NOTICE OF ALLOWANCE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LFSC","TVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669004601","title":"Travere Therapeutics, - Receives Uspto Notice of Allowance for Filspari Patent in Fsgs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669004601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669004601?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:04","pubTimestamp":1790161465,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nFWN45F0A1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100187","title":"Travere Gets USPTO Notice of Allowance for Filspari Use in FSGS Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100187","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100187?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:01","pubTimestamp":1790161289,"startTime":"0","endTime":"0","summary":"Travere gets USPTO notice of allowance for FILSPARI use in FSGS patent applicationTravere received a USPTO notice of allowance for a U.S. patent application covering methods of using FILSPARI (sparsen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDLM52zl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669108132","title":"Sensorion doubles down on GJB2 gene therapy as SENS-601 enters Phase I/II","url":"https://stock-news.laohu8.com/highlight/detail?id=2669108132","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669108132?lang=en_us&edition=fundamental","pubTime":"2026-09-23 14:24","pubTimestamp":1790144664,"startTime":"0","endTime":"0","summary":"An update from Sensorion SAS ( ($FR:ALSEN) ) is now available. Sensorion has sharpened its strategic focus on SENS-601, a single-vector AAV gene th...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sensorion-doubles-down-on-gjb2-gene-therapy-as-sens-601-enters-phase-i-ii?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","IBB","IBBQ","SYNB","FBT","BK4588","TBXU","CNCR","BK4585","GNOM","SENS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669175122","title":"New precision medicine venture gives Syngenis added firepower","url":"https://stock-news.laohu8.com/highlight/detail?id=2669175122","media":"The West Australian","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669175122?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:27","pubTimestamp":1790094446,"startTime":"0","endTime":"0","summary":"Syngenis has joined the renowned Perron Institute and Gene S founders in a precision-medicine venture that puts its integrated DNA and RNA platform to work and opens the door to recurring manufacturing revenue.","market":"hk","thumbnail":"https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg","type":0,"news_type":0,"thumbnails":["https://images.thewest.com.au/publication/C-22912933/bcb694b9b6d3ad9e7ac40e225d21b3d9b69e7435.jpg"],"rights":{"source":"thewest_stock","url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thewest.com.au/business/bulls-n-bears/new-precision-medicine-venture-gives-syngenis-added-firepower-c-22912933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thewest_stock","symbols":["TMAT","IIGF.AU","ZYAU.AU","FDIF","GIVE.AU","EES","IBB","HELX","E200.AU","IDNA","OZF.AU","EIGA.AU","VAS.AU","GNOM","HTEC","GEAR.AU","JDOC","IMLC.AU","BMED","SLF.AU","QRE.AU","DACE.AU","WDNA","IISV.AU","GNMX","XKO.AU","BBOZ.AU","GDOC","VAP.AU","IOZ.AU","BEAR.AU","SYNB","BK4588","XJO.AU","STW.AU","ADHD","PBE","XAO.AU","LFSC","OZR.AU","BK4585","XT","MEDX","QFN.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168643565","title":"Novo Nordisk CEO Signals Deal-Making Ambitions to Strengthen Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1168643565","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168643565?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:20","pubTimestamp":1790068822,"startTime":"0","endTime":"0","summary":"Novo Nordisk's chief executive has openly floated the possibility of acquisitions as the company navigates an increasingly crowded weight-loss drug market. Mike Doustdar, who leads the Danish...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XMMO","BK4588","BK4585","KCE","LFSC","CALF","MYLD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669198404","title":"Travere Therapeutics Announces Planned Chief Executive Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2669198404","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669198404?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:18","pubTimestamp":1790021936,"startTime":"0","endTime":"0","summary":"BRIEF-Travere Therapeutics Announces Planned Chief Executive Officer TransitionSept 22 (Reuters)-Travere Therapeutics, Inc.TVTX.O:TRAVERE THERAPEUTICS ANNOUNCES PLANNED CHIEF EXECUTIVE OFFICER TRANSIT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUA34RQPB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}